RT Journal Article
SR Electronic
T1 Exome first approach to reduce diagnostic costs and time – retrospective analysis of 111 individuals with rare neurodevelopmental disorders
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.23.21258974
DO 10.1101/2021.07.23.21258974
A1 Julia Klau
A1 Rami Abou Jamra
A1 Maximilian Radtke
A1 Henry Oppermann
A1 Johannes R. Lemke
A1 Skadi Beblo
A1 Bernt Popp
YR 2021
UL http://medrxiv.org/content/early/2021/07/24/2021.07.23.21258974.abstract
AB This single center study aims to determine the time, diagnostic procedure and cost saving potential of early exome sequencing in a cohort of 111 individuals with genetically confirmed neurodevelopmental disorders.We retrospectively collected data regarding diagnostic time points and procedures from the individuals’ medical histories and developed criteria for classifying diagnostic procedures in terms of requirement, followed by a cost allocation. The genetic variants of all individuals were reevaluated according to ACMG recommendations and considering the individuals’ phenotype.Individuals who developed first symptoms of their underlying genetic disorder when Next Generation Sequencing (NGS) diagnostics were already available received a diagnosis significantly faster than individuals with first symptoms before this cutoff. The largest amount of potentially dispensable diagnostics was found in genetic, metabolic, and cranial magnetic resonance imaging examinations. Out of 407 performed genetic examinations, 296 (72.7%) were classified as potentially dispensable. The same applied to 36 (27.9%) of 129 cranial magnetic resonance imaging and 111 (31.8%) of 349 metabolic examinations. Dispensable genetic examinations accounted 302,947.07€ (90.2%) of the total 335,837.49€ in potentially savable costs in this cohort. The remaining 32,890.42€ (9.8%) are related to non-required metabolic and cranial magnetic resonance imaging diagnostics. On average, the total potentially savable costs in our study amount to €3,025.56 per individual.Cost savings by first tier exome sequencing lie primarily in genetic, metabolic, and cMRI testing in this German cohort, underscoring the utility of performing exome sequencing at the beginning of the diagnostic pathway and the potential for saving diagnostic costs and time.Competing Interest StatementThe authors have declared no competing interest.Funding StatementB.P. is supported by the Deutsche Forschungsgemeinschaft (DFG) through grant PO2366/2-1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project was approved by the ethic committee of the University of Leipzig, Germany (224/16-ek and 402/16-ek).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analyzed during this study can be found in the online version of this article at the publisher's website.ACMGAmerican College of Medical GeneticscMRIcranial magnetic resonance imagingCNVcopy number variantDRGsDiagnosis Related GroupsECGelectrocardiogramEEGelectroencephalogramESexome sequencingGOÄGebührenordnung für ÄrzteMLPAmultiplex ligation-dependent probe amplificationNDDneurodevelopmental disorderNGSNext Generation SequencingqPCRquantitative polymerase chain reactionRT-PCRreverse transcription polymerase chain reactionSDstandard deviationSNVsingle-nucleotide variantUKLLeipzig University Medical CenterVUSvariants of uncertain significance